27258-32-8|1-Methyl-1H-pyrazole-3-carbaldehyde| Ambeed

Structure of 27258-32-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 27258-32-8 ] Purity: 98% HPLC SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 27258-32-8 ]

CAS No. :	27258-32-8
Formula :	C₅H₆N₂O
M.W :	110.11
SMILES Code :	C[N]1C=CC(=N1)C=O
MDL No. :	MFCD03419800
InChI Key :	QUYJEYSRBCLJIZ-UHFFFAOYSA-N
Pubchem ID :	7026090

Safety of [ 27258-32-8 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Computational Chemistry of [ 27258-32-8 ] Show Less

Physicochemical Properties

Num. heavy atoms	8
Num. arom. heavy atoms	5
Fraction Csp3	0.2
Num. rotatable bonds	1
Num. H-bond acceptors	2.0
Num. H-bond donors	0.0
Molar Refractivity	28.88
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	34.89 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	0.75
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	0.03
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	0.23
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	-0.63
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	0.5
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	0.18

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-0.94
Solubility	12.7 mg/ml ; 0.115 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-0.32
Solubility	53.3 mg/ml ; 0.484 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-0.68
Solubility	22.8 mg/ml ; 0.207 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	No
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	No
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-6.95 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	1.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	1.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	1.04

Application In Synthesis of [ 27258-32-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 27258-32-8 ]
Downstream synthetic route of [ 27258-32-8 ]

[ 27258-32-8 ] Synthesis Path-Upstream 1~6

1
[ 67751-23-9 ]
[ 60-34-4 ]
[ 27258-32-8 ]

Yield	Reaction Conditions	Operation in experiment
70%	With sodium hydroxide In water at 20℃;	methyl hydrazine (24 cm3, 19.5 g, 0.423 mol) was added dropwise to a solution of 17.0 g NaOH (0.423 mol) in 225 cm3 H2O upon cooling. Compound 16 (73.3 g,0.423 mol) was then added dropwise at rt, and the mixture was stirred overnight. Aq. HCl (36 percent, 28.2 g, 0.278 mol) was added upon cooling, the reaction mixture was stirred at rt for 1 h, and then extracted with CH2Cl2 (4 9 100 cm3). The combined organic phases were dried over Na2SO4, and the solvent was evaporated under reduced pressure. The residue was dissolved in 420 cm3 1 M aq. HCl and stirred at rt for 3 h. Then 10 percent aq K2CO3 was added to adjust pH = 10, and the mixture was extracted with CH2Cl2 (3 9 200 cm3). The organic layer was dried in vacuo and evaporated. The residue was distilled in vacuo to give 10a. Yield 32.8 g (70 percent); colorless liquid; b.p.: 70–72 °C (3 mbar); MS (ESI):m/z = 111 ([M+H]+); 1H NMR (500 MHz, CDCl3):d = 9.84 (s, 1H), 7.36 (d, J = 1.4 Hz, 1H), 6.68 (d,J = 1.4 Hz, 1H), 3.91 (s, 3H) ppm; 13C NMR (126 MHz,CDCl3): d = 185.8, 150.9, 131.8, 105.8, 39.2 ppm.

References: [1] Monatshefte fur Chemie, 2016, vol. 147, # 9, p. 1629 - 1636.

2
[ 25016-20-0 ]
[ 27258-32-8 ]

Yield	Reaction Conditions	Operation in experiment
63%	Stage #1: for 2 h; Heating / reflux Stage #2: With hydrogen In toluene for 8 h; Heating / reflux	A suspension of the acid (90 g, 0.71 mol) and DMF (1 drop) in thionyl chloride (250 mL) was stirred at reflux under nitrogen for 2 h. The solvent was evaporated from the reaction mixture, the residue azeotroped with toluene (3X200 mL), diluted into toluene (250 mL), added to a suspension OF PD-C (10 wtpercent, 9.3 g) in toluene (500 mL), and the mixture stirred at reflux for 8 h with a gentle flow of hydrogen gas through the suspension. After cooling to room temperature, the suspension was filtered through celite, washed with toluene, and concentrated in vacuo. The residue was fractionally distilled under vacuum to provide the title compound (50 g, 63percent) as a low melting white solid (bp = 92 °C COMMAT; 8 mmHg)

References: [1] Patent: WO2004/58702, 2004, A2, . Location in patent: Page 31; 24.

3
[ 84547-60-4 ]
[ 27258-32-8 ]

Yield	Reaction Conditions	Operation in experiment
63%	With hydrogen In toluene for 8 h; Heating / reflux	A stirred solution of 3-methylpyrazole (82.1 g, 1.0 mol) in water (3.5 L) was heated to 70 °C. Potassium permanganate (111 g, 0.70 mol) was added in one portion, keeping the temperature near 70 °C. The reaction mixture was stirred for 1 h at 70 °C, and then a second portion of potassium permanganate (111 g) was added at 70 °C. After 1 h, a final portion of potassium permanganate (111 g) was added at 70 °C. The reaction mixture was stirred a further 2 h at 70 °C, and any unreacted oxidant was reduced by the dropwise addition of isopropanol. The reaction mixture was cooled to room temperature, filtered, the solid was rinsed with water, and the filtrate evaporated to 500 mL. The aqueous was chilled to 0 °C, acidified with concentrated HC1, filtered, the solid product washed with water, and dried under vacuum to provide pyrazole- 3-carboxylic acid as a white solid (64.4 g, 57percent). Dimethyl sulfate (236 g, 177 ML, 1.87 mol) was added dropwise over 45 min to a stirred solution of pyrazole-3-carboxylic acid (200 g, 1.78 mol) in 20percent aqueous sodium hydroxide (850 ML) at 40 °C. The reaction mixture was heated at 80 °C for 2 h, cooled to room temperature, filtered, the filtrate acidified to pH 1 with concentrated HC1, the precipitate filtered, washed with water, and dried under vacuum to yield 1-METHYLPYRAZOLE-5-CARBOXYLIC acid (85 g, 38percent). The filtrate was concentrated in vacuo to 800 ML, extracted with chloroform (15X400 mL), the organic phase dried over anhydrous magnesium sulfate, concentrated in vacuo, and the residue recrystallized from isopropanol to yield 1-METHYLPYRAZOLE-3-CARBOXYLIC acid (74 g) as a white crystalline solid. A suspension of the acid (90 g, 0.71 mol) and DMF (1 drop) in thionyl chloride (250 ML) was stirred at reflux under nitrogen for 2 h. The solvent was evaporated from the reaction mixture, the residue azeotroped with toluene (3X200 mL), diluted into toluene (250 mL), added to a suspension of Pd-C (10 wtpercent, 9.3 g) in toluene (500 ML), and the mixture stirred at reflux for 8 h with a gentle flow of hydrogen gas through the suspension. After cooling to room temperature, the suspension was filtered through celite, washed with toluene, and concentrated in vacuo. The residue was fractionally distilled under vacuum to provide the title compound (50 g, 63percent) as a low melting white solid (bp = 92 °C COMMAT; 8 MMHG).

References: [1] Patent: WO2004/58763, 2004, A1, . Location in patent: Page 39-40.

4
[ 3920-50-1 ]
[ 74-88-4 ]
[ 27258-32-8 ]

Yield	Reaction Conditions	Operation in experiment
51.4%	With potassium carbonate In N,N-dimethyl-formamide at 20℃;	Add 1H-pyrazole-3-carbaldehyde (4.02 g, 41.8 mmol) to a 100 mL two-necked flask.Potassium carbonate (11.5 g, 83.2 mmol) and N,N-dimethylformamide (35 mL),Methyl iodide (3.89 mL, 62.5 mmol) was then added and stirred at room temperature overnight.Add water, extract with ethyl acetate (40 mL×6),The organic phase was washed with water (80 mL) and brine (EtOAc)Filter by suction, spin dry, and the residue was purified by silica gel column chromatography(petroleum ether/ethyl acetate (v/v) = 10/1),A pale yellow oil (2.37 g, 51.4percent) was obtained.

References: [1] Patent: CN108690016, 2018, A, . Location in patent: Paragraph 0420; 0422; 0423.

5
[ 67751-23-9 ]
[ 60-34-4 ]
[ 27258-32-8 ]
[ 27258-33-9 ]

Yield	Reaction Conditions	Operation in experiment
53%	Stage #1: With sodium hydroxide In water at 0 - 20℃; Stage #2: With hydrogenchloride In water for 4 h; Stage #3: With sodium hydroxide In water	12. Preparation of 1-methylpyrazole-3-carbaldehyde from 4-(dimethylamino)-1,1-dimethoxybut-3-en-2-oneWith cooling, methylhydrazine (151.3 g, 3.29 mol) was added dropwise to a solution of NaOH (131.4 g, 3.29 mol) in water (1700 ml). 4-(Dimethylamino)-1,1-dimethoxybut-3-en-2-one (569 g, 3.28 mol) was then added dropwise at room temperature, and the mixture was stirred overnight. Hydrochloric acid (36percent strength, 219.6 g, 2.17 mol) was added, and the reaction mixture was stirred for 4 h. Using aqueous sodium hydroxide solution (10percent strength), the reaction mixture was then adjusted to a pH of 9.4. After four extractions with methylene chloride (500 ml), the organic phases were washed with water, dried over magnesium sulfate and filtered, and the solvent was removed under reduced pressure. According to GC analysis, the oily residue had a purity of 73percent. In addition to the desired 1-methylpyrazole-3-carbaldehyde, the residue contained, as a byproduct, 10.7percent of the 5-carbaldehyde. This was removed by distillation under reduced pressure (transition temperature: 55° C. at 2.5 to 2.3 mbar). The yield of 1-methylpyrazole-3-carbaldehyde was 53percent. ¹H-NMR (CDCl₃): δ=4.05 (s, 3H) 6.8 (s, 1H), 7.5 (s, 1H), 9.95 ppm (s, 1H).

References: [1] Patent: US2010/174094, 2010, A1, . Location in patent: Page/Page column 16.

6
[ 84547-62-6 ]
[ 27258-32-8 ]

References: [1] Advanced Synthesis and Catalysis, 2009, vol. 351, # 16, p. 2715 - 2723.

[ 27258-32-8 ] Synthesis Path-Downstream 1~35

1
[ 27258-32-8 ]
[ 136609-85-3 ]
5-methyl-6-<2-(3-<1-methyl>pyrazolyl)-5-benzimidazoyl>-2,3,4,5-tetrahydro-pyridazin-3-one [ No CAS ]

References: [1]European Journal of Medicinal Chemistry,1993,vol. 28,p. 129 - 140.

2
[ 25016-20-0 ]
[ 27258-32-8 ]

Yield	Reaction Conditions	Operation in experiment
63%		A suspension of the acid (90 g, 0.71 mol) and DMF (1 drop) in thionyl chloride (250 mL) was stirred at reflux under nitrogen for 2 h. The solvent was evaporated from the reaction mixture, the residue azeotroped with toluene (3X200 mL), diluted into toluene (250 mL), added to a suspension OF PD-C (10 wtpercent, 9.3 g) in toluene (500 mL), and the mixture stirred at reflux for 8 h with a gentle flow of hydrogen gas through the suspension. After cooling to room temperature, the suspension was filtered through celite, washed with toluene, and concentrated in vacuo. The residue was fractionally distilled under vacuum to provide the title compound (50 g, 63percent) as a low melting white solid (bp = 92 °C COMMAT; 8 mmHg)

References: [1]Patent: WO2004/58702,2004,A2 .Location in patent: Page 31; 24.

3
[ 84547-60-4 ]
[ 27258-32-8 ]

Yield	Reaction Conditions	Operation in experiment
63%	With hydrogen;palladium 10% on activated carbon; In toluene; for 8h;Heating / reflux;	A stirred solution of 3-methylpyrazole (82.1 g, 1.0 mol) in water (3.5 L) was heated to 70 °C. Potassium permanganate (111 g, 0.70 mol) was added in one portion, keeping the temperature near 70 °C. The reaction mixture was stirred for 1 h at 70 °C, and then a second portion of potassium permanganate (111 g) was added at 70 °C. After 1 h, a final portion of potassium permanganate (111 g) was added at 70 °C. The reaction mixture was stirred a further 2 h at 70 °C, and any unreacted oxidant was reduced by the dropwise addition of isopropanol. The reaction mixture was cooled to room temperature, filtered, the solid was rinsed with water, and the filtrate evaporated to 500 mL. The aqueous was chilled to 0 °C, acidified with concentrated HC1, filtered, the solid product washed with water, and dried under vacuum to provide pyrazole- 3-carboxylic acid as a white solid (64.4 g, 57percent). Dimethyl sulfate (236 g, 177 ML, 1.87 mol) was added dropwise over 45 min to a stirred solution of pyrazole-3-carboxylic acid (200 g, 1.78 mol) in 20percent aqueous sodium hydroxide (850 ML) at 40 °C. The reaction mixture was heated at 80 °C for 2 h, cooled to room temperature, filtered, the filtrate acidified to pH 1 with concentrated HC1, the precipitate filtered, washed with water, and dried under vacuum to yield 1-METHYLPYRAZOLE-5-CARBOXYLIC acid (85 g, 38percent). The filtrate was concentrated in vacuo to 800 ML, extracted with chloroform (15X400 mL), the organic phase dried over anhydrous magnesium sulfate, concentrated in vacuo, and the residue recrystallized from isopropanol to yield 1-METHYLPYRAZOLE-3-CARBOXYLIC acid (74 g) as a white crystalline solid. A suspension of the acid (90 g, 0.71 mol) and DMF (1 drop) in thionyl chloride (250 ML) was stirred at reflux under nitrogen for 2 h. The solvent was evaporated from the reaction mixture, the residue azeotroped with toluene (3X200 mL), diluted into toluene (250 mL), added to a suspension of Pd-C (10 wtpercent, 9.3 g) in toluene (500 ML), and the mixture stirred at reflux for 8 h with a gentle flow of hydrogen gas through the suspension. After cooling to room temperature, the suspension was filtered through celite, washed with toluene, and concentrated in vacuo. The residue was fractionally distilled under vacuum to provide the title compound (50 g, 63percent) as a low melting white solid (bp = 92 °C COMMAT; 8 MMHG).

References: [1]Patent: WO2004/58763,2004,A1 .Location in patent: Page 39-40.

4
[ 911491-26-4 ]
[ 27258-32-8 ]
N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-8-[(1-methyl-1H-pyrazol-3-yl)methyl]-4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[1,2-a]pyrimidine-2-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With sodium cyanoborohydride; acetic acid; In methanol; at 20℃; for 48h;	To a solution of N-(4-fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-6,7,8,9-tetrahydro- 4H-pyrazino[l,2-alpha]pyrimidine-2-carboxamide (prepared as described in Example 1, Step 1-2) in MeOH and AcOH (5 eq.) was added l-methyl-lH-pyrazole-3-carbaldehyde (2 eq.) and then NuaBEta3CNu (1.5 eq.).The mixture was left to stir for 48 hours at room temperature during which time further additions of the aldehyde (1.5 eq.) was necessary to drive the reaction to completion. After concentration under reduced pressure the crude residue was purified by RP HPLC (Ci 8, 5 muM, H2psi/MeCN with 1percent of TFA as eluant) affording the title product as TFA salt. iH-NMR (300 MHz, d6-DMSO) delta 12.32 (bs, 1 H), 9.51 (t, J= 6.3 Hz, 1 H), 7.74 (d, J = 1.5 Hz, IH), 7.38 (dd, J= 8.6 Hz, J= 5.7 Hz, 2 H), 7.18 (t, J= 8.6 Hz, 2 H), 6.36 (d, J= 1.5 Hz, 1 H), 4.49 (d, J= 6.3 Hz, 2 H), 4.14 (br. S, 2 H), 3.86 (m, 5 H), 3.37 (bs, 2 H), 1.77 (s, 6 H); MS (ES) C22H25FN6O3 requires 440, found: 441 (M+H.div.).

References: [1]Bioorganic and Medicinal Chemistry Letters,2009,vol. 19,p. 4245 - 4249.
[2]Patent: WO2006/103399,2006,A1 .Location in patent: Page/Page column 69.

5
[ 27258-32-8 ]
[ 942316-95-2 ]

Yield	Reaction Conditions	Operation in experiment
74.4%		(E)-2-terr-butoxycarbonylamino-3-(l-methyl-lH-pyrazol-3- yl)-acrylic acid methyl ester: Boc-methyl-2-(dimethylphosphono)glycinate (1.620 g, 5.45 mmol) was dissolved in CH2CI2 (10 mL) and stirred under nitrogen at it To this solution was added DBU (0.753 mL, 4.99 mmol) and the mixture was stirred for 10 min, followed by dropwise addition of a solution of 1 -methyl- lH-pyrazole-3- carbaldehyde (0.5 g, 4.54 mmol) in CH2Cl2 (10 mL) over 15-20 min. Stirring was continued at rt overnight. The solvent was removed on a rotary evaporator and the residue was taken up in a mixture OfCH2Cl2ZEtOAc, washed with 5percent citric acid and <n="159"/>brine, then dried over anhydrous sodium sulfate, filtered and evaporated. The residue was dissolved in methylene chloride and charged to a 120 g silica gel cartridge which was eluted with a 30 min gradient from 0-60percent EtOAc in hexane to provide the olefin product (0.95 g, 74.4percent) as a thick viscous oil. 1HNMR (500 MHz, CDCl3) delta: 8.49 (1 H, s), 7.32 (1 H, d, J=2.2 Hz), 6.50 (1 H, s), 6.28 (1 H, d, /=2.2 Hz), 3.94 (3 H, s), 3.84 (3 H, s), 1.48 (9 H, s). LCMS m/z 226. lv(M+H-tBu)+; 182.2 (M+H-Boc)+.

References: [1]Patent: WO2007/70826,2007,A1 .Location in patent: Page/Page column 156-157.

6
[ 121056-95-9 ]
[ 27258-32-8 ]
[ 942316-95-2 ]

Yield	Reaction Conditions	Operation in experiment
74.4%	With 1,8-diazabicyclo[5.4.0]undec-7-ene; In dichloromethane; at 20℃;	Boc-methyl-2-(dimethylphosphono)glycinate (1.620 g, 5.45 mmol) was dissolved in Ceta2CI2 (10 mL) and stirred under nitrogen at rt. To this solution was added DBU (0.753 mL, 4.99 mmol) and the mixture was stirred for 10 min, followed by dropwise addition of a solution of 1 -methyl- IH- pyrazole-3-carbaldehyde (0.5 g, 4.54 mmol) in CH2Cl2 (10 mL) over 15-20 min. Stirring was continued at rt overnight. The solvent was removed on a rotary evaporator and the residue was taken up in a mixture of CH2Cl2ZEtOAc, washed with 5percent citric acid and brine, then dried over anhydrous sodium sulfate, filtered and evaporated. The residue was dissolved in methylene chloride and charged to a 120 g silica gel cartridge which was eluted with a 30 min gradient from 0-60percent EtOAc in hexane to provide the olefin product (0.95 g, 74.4percent) as a thick viscous oil. MS: m/z 226.1 [M + H-IBu]+. 1H NMR (500 MHz, CDCl3) delta: 8.49 (1 H, s), 7.32 (1 H, d, J=2.2Hz), 6.50 (1 H, s), 6.28 (1 H, d, J=2.2 Hz), 3.94 (3 H, s), 3.84 (3 H, s), 1.48 (9 H, s) ppm.

References: [1]Patent: WO2008/157162,2008,A1 .Location in patent: Page/Page column 94-95.

7
[ 27258-32-8 ]
[ 1214997-78-0 ]

References: [1]Advanced Synthesis and Catalysis,2009,vol. 351,p. 2715 - 2723.

8
[ 84547-62-6 ]
[ 27258-32-8 ]

References: [1]Advanced Synthesis and Catalysis,2009,vol. 351,p. 2715 - 2723.

9
[ 264264-31-5 ]
[ 27258-32-8 ]
[ 1204828-81-8 ]

Yield	Reaction Conditions	Operation in experiment
	With 1,8-diazabicyclo[5.4.0]undec-7-ene; lithium chloride; In acetonitrile; for 1h;Molecular sieve;	/.7.1 Intermediate 21; A 25ml round-bottomed flask was charged with lithium chloride (0.366 g, 8.64 mmol), 1 -methyl- lH-pyrazole- 3-carbaldehyde (0.951 g, 8.64 mmol), and tert-butyl 7-acetyl-4,5-dihydro-lH-benzo[d]azepine-3(2H)- carboxylate (2.5 g, 8.64 mmol) in acetonitrile (10 ml) to give a colourless solution. DBU (1.302 ml, 8.64 mmol) was added and 4A molecular sieves. The reaction was stirred for one hour.The solvent was evaporated and the residue was taken up into ethyl acetate and washed with 5percent citric acid (x2), saturated sodium bicarbonate, and dried and evaporated. The residue was purified by Biotage 5Og SNAP column using 50percent EtOAc/ Petrol to yield pure (E)-tert-butyl 7-(3-(l-methyl-lH-pyrazol-3-yl)acryloyl)-4,5-dihydro-lH- benzo[d]azepine-3(2H)-carboxylate (6.82 mmol)MS ES+ : 3261H NMR (400 MHz, MeOD): delta 7.80 - 7.85 (m, 2H), 7.64 - 7.66 (m, 2H), 7.60 - 7.63 (m, IH), 7.27 - 7.32 (m, IH), 6.75 - 6.78 (m, IH), 3.92 (s, 3H), 3.56 (br. s., 4H), 2.95 - 3.02 (m, 4H), 1.44 (s, 9H)

References: [1]Patent: WO2010/7382,2010,A1 .Location in patent: Page/Page column 32-33.

10
[ 27258-32-8 ]
4-bromo-1-methyl-1H-pyrazole-3-carbaldehyde [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
78%	With N-Bromosuccinimide; In N,N-dimethyl-formamide; at 50℃; for 2h;	To a solution of <strong>[27258-32-8]1-methyl-1H-pyrazole-3-carbaldehyde</strong> (150 g, 1.36 mol) in DMF (1000 mL) was added NBS (240 g, 1.35 mol). The resulting solution was stirred for 2 h at 50° C. and then was quenched by the addition of ice water (2000 mL). The reaction mixture was cooled to ?10° C. with an ice/salt bath, and the solids were collected by filtration to provide the desired product as a white solid (200 g, 78percent). 1H NMR (300 MHz, CDCl3): delta 9.90 (d, J=0.7 Hz, 1H), 7.46 (s, 1H), 3.96 (s, 3H) ppm.
61.3%	With N-Bromosuccinimide; In N,N-dimethyl-formamide; at 3 - 20℃;	13.1 Preparation of 4-bromo-<strong>[27258-32-8]1-methylpyrazole-3-carbaldehyde</strong> by bromination of <strong>[27258-32-8]1-methylpyrazole-3-carbaldehyde</strong>At 3-5° C., a solution of N-bromosuccinimide (NBS, 64.6 g, 0.36 mol) in dimethyl-formamide (DMF, 160 ml) was added dropwise (slightly exothermic) to a solution of <strong>[27258-32-8]1-methylpyrazole-3-carbaldehyde</strong> (40 g, 0.36 mol) in DMF (320 ml). The reaction mixture was then heated to room temperature and stirred for a further 2 h. The reaction mixture was then added with stirring to a mixture of water (1400 ml) and aqueous sodium hydroxide solution (conc., 15 ml) and extracted four times with methyl tert-butyl ether (MTBE, 100 ml). The organic phases were combined and washed with saturated NaCl solution, dried over magnesium sulfate and filtered, and the solvent was then removed under reduced pressure. This gave 4-bromo-<strong>[27258-32-8]1-methylpyrazole-3-carbaldehyde</strong> as a solid (42.9 g, 98percent pure according to GC analysis, yield 61.3percent).1H-NMR (CDCl3): delta=4.0 (s, 3H), 7.55 (s, 1H), 9.95 ppm (s, 1H); 13C-NMR (CDCl3): delta=40.3, 95.1, 133.0, 146.5, 184.6 ppm.

References: [1]Patent: US2016/243100,2016,A1 .Location in patent: Paragraph 0197-0198.
[2]Patent: US2010/174094,2010,A1 .Location in patent: Page/Page column 16.

11
[ 67751-23-9 ]
[ 60-34-4 ]
[ 27258-32-8 ]
[ 27258-33-9 ]

Yield	Reaction Conditions	Operation in experiment
53%; 10.7%Chromat.		12. Preparation of 1-methylpyrazole-3-carbaldehyde from 4-(dimethylamino)-1,1-dimethoxybut-3-en-2-oneWith cooling, methylhydrazine (151.3 g, 3.29 mol) was added dropwise to a solution of NaOH (131.4 g, 3.29 mol) in water (1700 ml). 4-(Dimethylamino)-1,1-dimethoxybut-3-en-2-one (569 g, 3.28 mol) was then added dropwise at room temperature, and the mixture was stirred overnight. Hydrochloric acid (36% strength, 219.6 g, 2.17 mol) was added, and the reaction mixture was stirred for 4 h. Using aqueous sodium hydroxide solution (10% strength), the reaction mixture was then adjusted to a pH of 9.4. After four extractions with methylene chloride (500 ml), the organic phases were washed with water, dried over magnesium sulfate and filtered, and the solvent was removed under reduced pressure. According to GC analysis, the oily residue had a purity of 73%. In addition to the desired 1-methylpyrazole-3-carbaldehyde, the residue contained, as a byproduct, 10.7% of the 5-carbaldehyde. This was removed by distillation under reduced pressure (transition temperature: 55 C. at 2.5 to 2.3 mbar). The yield of 1-methylpyrazole-3-carbaldehyde was 53%. 1H-NMR (CDCl3): delta=4.05 (s, 3H) 6.8 (s, 1H), 7.5 (s, 1H), 9.95 ppm (s, 1H).

References: [1]Patent: US2010/174094,2010,A1 .Location in patent: Page/Page column 16.

12
[ 27258-32-8 ]
[ 1089212-37-2 ]

Yield	Reaction Conditions	Operation in experiment
66.8%	With diethylamino-sulfur trifluoride; In dichloromethane; at -20 - 20℃;	17. Preparation of 3-difluoromethyl-1-methylpyrazole from <strong>[27258-32-8]1-methylpyrazole-3-carbaldehyde</strong>At -20° C., (diethylamino)sulfur trifluoride (DAST, 87.8 g, 0.54 mol) was added dropwise to a solution of <strong>[27258-32-8]1-methylpyrazole-3-carbaldehyde</strong> (20 g, 0.18 mol) in methylene chloride (200 ml). The reaction mixture was stirred at room temperature overnight. The reaction mixture was then added carefully to ice/water (400 g) and extracted twice with methylene chloride (100 ml each). The combined organic phase was washed twice with water (100 ml each) and twice with NaCl solution (100 ml each) and dried over magnesium sulfate, and the solvent was removed under reduced pressure. The residue was separated by fractional distillation. 3-Difluoromethyl-1-methylpyrazole (16.5 g, transition temperature 141° C. at 570 mbar) was isolated in a purity of 95percent. This corresponds to a yield of 66.8percent.
	With diethylamino-sulfur trifluoride; In dichloromethane; at 0 - 20℃;	To a solution of <strong>[27258-32-8]1-methyl-1H-pyrazole-3-carbaldehyde</strong> (4.00 g, 36.33 mmol) in CH2Cl2 (50 mL) at 0° C. was added DAST (23.4 g, 145.17 mmol, 4.00 equiv) dropwise. The reaction mixture was stirred overnight at room temperature and then was quenched by the addition of saturated NaHCO3 (100 mL), and extracted with CH2Cl2 (3×200 mL). The combined organic layers were dried over anhydrous MgSO4, filtered and concentrated to provide the desired product as an oil (4.8 g, crude) which was used in the next reaction without further purification. 1H NMR (400 MHz, CDCl3): delta 7.32-7.37 (m, 1H), 6.44-6.45 (t, 1H), 6.80 (m, 1H), 3.90 (s, 3H) ppm.

References: [1]Patent: US2010/174094,2010,A1 .Location in patent: Page/Page column 17.
[2]Patent: US2016/243100,2016,A1 .Location in patent: Paragraph 0170-0171.

13
[ 4309-26-6 ]
[ 27258-32-8 ]
[ 1309584-49-3 ]

Yield	Reaction Conditions	Operation in experiment
51%	With sodium acetate; acetic acid; for 10h;Reflux;	Example 4Synthetic Pathway of Compound D (7084175)(E)-3-(3-(dihydroxyamino)phenyl)-2-(2-(1-methyl-1H-pyrazol-3-yl)vinyl)quinazolin-4(3H)-oneA mixture of 2-methyl-3-(3-nitrophenyl)-3H-quinazolin-4-one (for synthesis 1 see preparation of Compound A 165 mg, 0.6 mmol), <strong>[27258-32-8]1-methyl-1H-pyrazole-3-carbaldehyde</strong> (120 mg, 0.70 mmol) and NaOAc (53 mg, 0.70 mmol) in glacial acetic acid (3.0 ml) was heated at reflux 10 hours. After the reaction mixture was allowed to cool to RT the resulting precipitate was collected by vacuum filtration, washed with water and recrystallized from EtOH to afford 114 mg (51percent) of the target compound.

References: [1]Patent: US2011/129463,2011,A1 .Location in patent: Page/Page column 10.

14
[ 384835-91-0 ]
[ 27258-32-8 ]
[ 1355994-27-2 ]

Yield	Reaction Conditions	Operation in experiment
35%		To a solution of ethyl 3-amino-l-(4-methoxybenzyl)- lH-pyrazole-4-carboxylate (573 mg, 2.08 mmol) in DCM (20 mL) was added 1 - methyl-lH-pyrazole-3-carbaldehyde (229 mg, 2.08 mmol) and AcOH (5.96 mL, 104 mmol). After cooling the reaction mixture to 0°C, NaBH(OAc)3 (882 mg, 4.16 mmol) was added portionwise and the reaction mixture was stirred at rt for 1 day. The mixture was quenched with an aqueous NaHC03 solution. The aqueous layer was extracted 3 times with DCM. The organic layers were combined, dried over MgS04, filtered and concentrated under reduced pressure. The crude residue was purified by flash chromatography over silica gel using cyclohexane EtOAc (100:0 to 0: 100) as eluent to yield the title compound (0.73 mmol, 270 mg, 35percent).UPLC-MS: RT = 0.92 min; MS m/z ES+= 370.

References: [1]Patent: WO2012/9001,2012,A2 .Location in patent: Page/Page column 45.

15
[ 942949-34-0 ]
[ 27258-32-8 ]
[ 1402709-81-2 ]

References: [1]Journal of Medicinal Chemistry,2012,vol. 55,p. 8721 - 8734,14.

16
[ 27258-32-8 ]
[ 1421236-95-4 ]
(R)-N-(3-((S)-4-benzyl-5,5-dimethyl-2-oxooxazolidin-3-yl)-2-methyl-1-(1-methyl-1H-pyrazol-3-yl)-3-oxopropyl)-2-methylpropane-2-sulfinamide [ No CAS ]

References: [1]Organic Letters,2013,vol. 15,p. 562 - 565.

17
[ 27258-32-8 ]
[ 196929-78-9 ]
[ 1421236-70-5 ]

References: [1]Organic Letters,2013,vol. 15,p. 562 - 565.

18
[ 1032289-55-6 ]
[ 27258-32-8 ]
4-(2,5-dimethyl-1H-pyrrol-1-yl)-1-((1-methyl-1H-pyrazol-3-yl)methyl)piperidine [ No CAS ]